Evidence map›Paper›PMID 26152742›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.

Sharon E Johnatty, Jonathan P Tyrer, Siddhartha Kar, Jonathan Beesley, Yi Lu, Bo Gao, Peter A Fasching, Alexander Hein, Arif B Ekici, Matthias W Beckmann and 94 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Identification of a Locus NearCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

104 authors at 20 institutions in 10 countries.

Sharon E JohnattyDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Jonathan P TyrerDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Siddhartha KarDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Jonathan BeesleyDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Yi LuDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Bo GaoDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Center for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney, New South Wales, Australia.
Peter A FaschingDivision of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California. University Hospital Erlangen, Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Alexander HeinUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Arif B EkiciUniversity Hospital Erlangen, Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Matthias W BeckmannUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium. Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium.
Els Van NieuwenhuysenDepartment of Gynecologic Oncology, Leuven Cancer Institute, University of Leuven, Leuven, Belgium.
Ignace VergoteDepartment of Gynecologic Oncology, Leuven Cancer Institute, University of Leuven, Leuven, Belgium.
Sandrina LambrechtsDepartment of Gynecologic Oncology, Leuven Cancer Institute, University of Leuven, Leuven, Belgium.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington.
Jennifer A DohertyDepartment of Community and Family Medicine, Section of Biostatistics and Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Jenny Chang-ClaudeGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Francesmary ModugnoDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. Women's Cancer Research Program, Magee-Women's Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Roberta B NessThe University of Texas School of Public Health, Houston, Texas.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Douglas A LevineGynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Lambertus A KiemeneyRadboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, the Netherlands.
Leon F A G MassugerRadboud University Medical Centre, Radboud Institute for Molecular Sciences, Nijmegen, the Netherlands.
Jacek GronwaldInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Jan LubińskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Anna JakubowskaInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Louise BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Honglin SongDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Valerie RheniusDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Ian CampbellCancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Diana EcclesFaculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, Hampshire, United Kingdom.
Weiva SiehDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Alice S WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Joseph H RothsteinDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Rebecca SutphenEpidemiology Center, College of Medicine, University of South Florida, Tampa, Florida.
Hoda Anton-CulverDepartment of Epidemiology, Center for Cancer Genetics Research and Prevention, School of Medicine, University of California Irvine, Irvine, California.
Argyrios ZiogasDepartment of Epidemiology, University of California Irvine, Irvine, California.
Simon A GaytherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
Aleksandra Gentry-MaharajWomen's Cancer, UCL EGA Institute for Women's Health, London, United Kingdom.
Usha MenonWomen's Cancer, UCL EGA Institute for Women's Health, London, United Kingdom.
Susan J RamusDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
Celeste L PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Daniel O StramDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
Jolanta KupryjanczykDepartment of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Agnieszka Dansonka-MieszkowskaDepartment of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Iwona K RzepeckaDepartment of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Beata SpiewankiewiczDepartment of Gynecologic Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Marc T GoodmanCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
Michael E CarneyCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
Pamela J ThompsonCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany. Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Andreas du BoisDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany. Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Ira SchwaabInstitut für Humangenetik Wiesbaden, Wiesbaden, Germany.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany. Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Jacobus PistererZentrum für Gynäkologische Onkologie, Kiel, Germany.
Peter HillemannsDepartment of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany.
AGO Study Group
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Christine WalshWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Sandra OrsulicWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Stacey J WinhamDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Madalene EarpDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Melissa C LarsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Zachary C FogartyDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Estrid HøgdallDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Susanne Kruger KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Brooke L FridleyBiostatistics and Informatics Shared Resource, University of Kansas Medical Center, Kansas City, Kansas.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Robert A VierkantDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Joellen M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina. Cancer Control and Population Sciences, Duke Cancer Institute, Durham, North Carolina.
Edwin S IversenDepartment of Statistical Science, Duke University, Durham, North Carolina.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Harvard School of Public Health, Boston, Massachusetts.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Harvard School of Public Health, Boston, Massachusetts.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, The State University of New Jersey, New Brunswick, New Jersey.
Irene OrlowMemorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, Epidemiology Service, New York, New York.
Tanja PejovicDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon. Knight Cancer Institute, Portland, Oregon.
Yukie BeanDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon. Knight Cancer Institute, Portland, Oregon.
Claus HøgdallDepartment of Gynaecology, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Lene LundvallDepartment of Gynaecology, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ian McNeishInstitute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom.
James PaulCancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Karen CartyCancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Nadeem SiddiquiDepartment of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Rosalind GlasspoolCancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Thomas SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Catherine KennedyDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Center for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney, New South Wales, Australia.
Yoke-Eng ChiewDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Center for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney, New South Wales, Australia.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Stuart MacGregorDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Paul D P PharoahDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Ellen L GoodeDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Anna deFazioDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Center for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney, New South Wales, Australia.
Penelope M WebbDepartment of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Georgia Chenevix-TrenchDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. georgia.trench@qimrberghofer.edu.au.
Australian Ovarian Cancer Study Group
Cedars-Sinai Medical Center · USQIMR Berghofer Medical Research Institute · AUUniversity of Southern California · USBeatson West of Scotland Cancer Centre · GBMillennium Institute · BRThe Maria Sklodowska-Curie National Research Institute of Oncology · PLInternational Hereditary Cancer Center · PLMayo Clinic in Florida · USStanford Health Care · USDuke University · USHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEUniversity of Copenhagen · DKVIB-KU Leuven Center for Cancer Biology · BEBridge University · SSBrigham and Women's Hospital · USCancer Center of Hawaii · USComprehensive Cancer Center Erlangen · DECopenhagen University Hospital · DKDepartment of Public Health · USHerlev Hospital · DK

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 1985 to 2009
$18.2M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
Cancer Research UK 10124Cancer Research UK 15960Cancer Research UK 16561Cancer Research UK A10119Cancer Research UK A13086Cancer Research UK C12292/A11174Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A10710Cancer Research UK C490/A10119Cancer Research UK C490/A10124Cancer Research UK C490/A16561Cancer Research UK C490/A6187Cancer Research UK C490/A8339Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C536/A13086Cancer Research UK C536/A6689Cancer Research UK C8197/A16565CIHRMedical Research Council MR/N005813/1NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NCI NIH HHS 1U19 CA148065NCI NIH HHS 1U19 CA148112NCI NIH HHS 1U19 CA148537NCI NIH HHS CA128978NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA095666NCI NIH HHS K07-CA80668NCI NIH HHS K22 CA138563NCI NIH HHS K22-CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01CN025403NCI NIH HHS N01 PC067010NCI NIH HHS N01PC67010NCI NIH HHS NIH R01-CA112523NCI NIH HHS P01 CA017054NCI NIH HHS P01CA17054NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA072720NCI NIH HHS P30-CA072720NCI NIH HHS P30CA14089NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS P50-CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA 058598NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01-CA126841NCI NIH HHS R01 CA128978NCI NIH HHS R01CA61132NCI NIH HHS R01 CA83918NCI NIH HHS R01-CA87538NCI NIH HHS R03 CA113148NCI NIH HHS R03CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R03CA115195NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCRR NIH HHS M01 RR000056NCRR NIH HHS M01-RR000056
6 · The paper itself

Abstract

purposeChemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. EXPERIMENTAL

designWe analyzed approximately 2.8 million genotyped and imputed SNPs from the iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 European epithelial ovarian cancer (EOC) patients who underwent first-line treatment of cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 patients treated with ≥ 4 cycles of paclitaxel and carboplatin at standard doses. We evaluated the top SNPs in 4,434 EOC patients, including patients from The Cancer Genome Atlas. In addition, we conducted pathway analysis of all intragenic SNPs and tested their association with PFS and OS using gene set enrichment analysis.

resultsFive SNPs were significantly associated (P ≤ 1.0 × 10(-5)) with poorer outcomes in at least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22), were located in long noncoding RNAs (lncRNAs) RP11-179A10.1, RP11-314O13.1, and RP11-284F21.8, respectively (P ≤ 7.1 × 10(-6)). ENCODE ChIP-seq data at 1q22 for normal ovary show evidence of histone modification around RP11-284F21.8, and rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, expression levels of which were reportedly associated with prognosis in another solid tumor. YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy (pGSEA ≤ 6 × 10(-3)).

conclusionsWe have identified SNPs in three lncRNAs that might be important targets for novel EOC therapies.

Indexed as

Genome-Wide Association StudyQuantitative Trait LociAllelesCarcinoma, Ovarian EpithelialComputational BiologyFemaleGenotypeHumansKaplan-Meier EstimateMeta-Analysis as TopicNeoplasms, Glandular and EpithelialOvarian NeoplasmsPatient Outcome AssessmentPolymorphism, Single NucleotidePrognosis

Identifiers

PMID26152742
PMCPMC4624261
OpenAlexW1840612622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.